Health · 1 views

Aficamten trial brings positive news for patients living with non-obstructive hypertrophic cardiomyopathy

Aficamten treatment was associated with significant improvements in symptom burden and exercise capacity in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, according to results presented today in a Hot Line session…

Source Story Brief Updated 1h 10m ago

Story intelligence Beta

Confidence Limited Single-outlet story

Views 1 Community interest

Brief read ~52 words

Story Brief

Hypertrophic cardiomyopathy (HCM) is an inherited disease in which the heart muscle becomes abnormally thick. HCM can be obstructive, when the thickened muscle blocks blood flow, or non-obstructive, when blood flow is not blocked but heart function is still affected. "Patients with non-obstructive HCM experience limiting symptoms that affect their daily lives.

Read full article on Medical Xpress

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page